Insulin Aspart
drugOn this page
Also known as FiaspFiasp flextouchI-004I004INA-X14Ins novorapidInsulin aspart recombinantInsulin aspart sanofiINSULIN X14Insulina aspartaInsuline asparteKirsty (previously kixelle)NovologNovorapid
Summary
Insulin Aspart (CHEMBL1201496) is an approved protein (ATC A10AD05); indicated across 12 conditions including diabetes mellitus and leukemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: A10AD05 (+1 more)
- Indications: 12 conditions
- Clinical trials: 270
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201496 |
| Name | Insulin Aspart |
| Type | Protein |
| Max phase | 4 |
| ATC | A10AD05, A10AB05 |
Also known as: Fiasp, Fiasp flextouch, I-004, I004, INA-X14, Ins novorapid, Insulin aspart, Insulin aspart recombinant, Insulin aspart sanofi, INSULIN X14, Insulina asparta, Insuline asparte
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
12 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diabetes mellitus | 4 | MONDO:0005015 | EFO:0000400 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| gestational diabetes | 3 | MONDO:0005406 | EFO:0004593 |
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| atherosclerosis | 3 | MONDO:0005311 | EFO:0003914 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| cystic fibrosis | 3 | MONDO:0009061 | MONDO:0009061 |
| Alzheimer disease | 1 | MONDO:0004975 | MONDO:0004975 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 270.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 82 |
| PHASE1 | 67 |
| PHASE4 | 57 |
| Not specified | 43 |
| PHASE2 | 11 |
| PHASE2/PHASE3 | 5 |
| EARLY_PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00095446 | PHASE4 | COMPLETED | NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes |
| NCT00117780 | PHASE4 | COMPLETED | Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes |
| NCT00121966 | PHASE4 | COMPLETED | South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus |
| NCT00254085 | PHASE4 | UNKNOWN | Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes. |
| NCT00274274 | PHASE4 | COMPLETED | Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes |
| NCT00282451 | PHASE4 | COMPLETED | Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes |
| NCT00365170 | PHASE4 | COMPLETED | Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes |
| NCT00449839 | PHASE4 | COMPLETED | Changes of the Infusion Rate in Insulin Pump Treatment |
| NCT00461331 | PHASE4 | COMPLETED | Comparison of Insulins Aspart and Lispro in Insulin Pumps |
| NCT00494988 | PHASE4 | COMPLETED | Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart |
| NCT00509925 | PHASE4 | TERMINATED | Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes |
| NCT00537303 | PHASE4 | COMPLETED | Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes |
| NCT00542620 | PHASE4 | COMPLETED | Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial |
| NCT00571935 | PHASE4 | COMPLETED | Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes |
| NCT00572806 | PHASE4 | COMPLETED | Initiation of Insulin Aspart in Type 2 Diabetes |
| NCT00591227 | PHASE4 | COMPLETED | Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol. |
| NCT00593255 | PHASE4 | COMPLETED | Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes |
| NCT00597233 | PHASE4 | COMPLETED | Human Insulin NPH and Insulin Aspart in Type 1 Diabetes |
| NCT00607087 | PHASE4 | COMPLETED | Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus |
| NCT00657943 | PHASE4 | COMPLETED | The Copenhagen Insulin and Metformin Therapy Trial |
| NCT00676819 | PHASE4 | COMPLETED | Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes |
| NCT00747409 | PHASE4 | UNKNOWN | Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes |
| NCT00821795 | PHASE4 | COMPLETED | Veterans Inpatient Insulin Study and Transition to Outpatient Therapy |
| NCT00913497 | PHASE4 | COMPLETED | The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children |
| NCT00965549 | PHASE4 | COMPLETED | Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients |
| NCT01068652 | PHASE4 | COMPLETED | Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs |
| NCT01165684 | PHASE4 | COMPLETED | Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen |
| NCT01212913 | PHASE4 | COMPLETED | Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) |
| NCT01293396 | PHASE4 | COMPLETED | Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids |
| NCT01407289 | PHASE4 | COMPLETED | A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia |
| NCT01417897 | PHASE4 | UNKNOWN | Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study |
| NCT01467141 | PHASE4 | COMPLETED | Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes |
| NCT01486966 | PHASE4 | TERMINATED | Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes |
| NCT01526733 | PHASE4 | COMPLETED | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase |
| NCT01649570 | PHASE4 | COMPLETED | Safety and Efficacy of Insulin Aspart in Type 2 Diabetes |
| NCT01678235 | PHASE4 | COMPLETED | Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus |
| NCT01697631 | PHASE4 | COMPLETED | Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| NCT01848990 | PHASE4 | COMPLETED | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) |
| NCT01966978 | PHASE4 | COMPLETED | The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study |
| NCT02192450 | PHASE4 | COMPLETED | Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).